Newron Balances Funding Certainty with FDA Speed Bump in Schizophrenia Drug Race

Despite a 45% stock drop and FDA partial clinical hold on Evenamide's phase III trial, Newron has financing through 2027 and analysts see 200% upside.

Newron SpA finds itself in a split-screen scenario. The biotech's shares have tumbled nearly 45% since the start of the year, yet the company has locked down enough financing to keep operations running well into 2027. The contradiction sums up the mood around the Italian drug developer: a solid cash position colliding with a regulatory setback that has sent the stock reeling.

A €15 million equity raise in February was followed by a second tranche of €11 million, contingent on clinical milestones, that should land before the end of 2026. Those funds, combined with a renegotiated repayment schedule on a 2018 loan from the European Investment Bank, give Newron breathing room. The shares ended last week at €14.70, more than 55% below the January high of €32.95 but still roughly 70% higher than twelve months ago.

FDA halt casts shadow over key US centers

The source of the recent pressure emerged in late April, when Newron disclosed a partial clinical hold imposed by the US Food and Drug Administration. The regulatory brake stops enrollment at American sites participating in the ENIGMA TRS?2 phase?III study of Evenamide, the company’s candidate for treatment?resistant schizophrenia. The setback has injected fresh uncertainty into the timeline of the pivotal trial.

Outside the US, the programme continues without interruption. EA Pharma, a subsidiary of the Eisai group that holds rights to Evenamide in Japan and selected Asian markets, launched its own phase?III study in January. That parallel track gives Newron at least one clinical front moving forward while the FDA dialogue plays out.

Analysts hold the line despite the stock rout

Wall Street has not abandoned the story. Three analysts maintain buy ratings, with a consensus price target of €51.37 — implying upside of more than 200% from current levels. The bull case rests on Evenamide’s potential as a first?in?class add?on therapy for schizophrenia patients who do not respond adequately to standard antipsychotics.

The binary nature of biotechnology investing is on full display. The main ENIGMA TRS?2 study will enroll at least 600 patients, while a parallel investigation adds another 400 subjects. Management still expects to report top?line data from the primary study in the fourth quarter of 2026. That readout, more than any interim event, will determine the drug’s commercial fate.

Conference circuit and chart signals

Newron’s executive team is taking the message on the road. The company is attending the German Spring Conference 2026 through May 13, where investors will press for clarity on how the FDA hold might shift the overall timeline. Later in June, Newron will present at the BIO International Convention in San Diego, scouting for additional development and commercialisation partners for Evenamide.

On the technical side, the stock’s chart has deteriorated. The current price sits well below the 200?day moving average, which runs at €17.65. That long?term trendline often acts as a proxy for institutional sentiment, and its breach signals a cautious near?term outlook.

Shareholders added two new independent directors to the supervisory board in April. The company’s next scheduled financial update is the half?year report on September 22. Until then, the market’s focus will be on any word from the FDA regarding the status of the partial hold — and on whether Newron can keep the narrative centred on the €11 million tranche and the looming fourth?quarter data point that will decide the next chapter for Evenamide.